RBC Capital Keeps Their Buy Rating on Jasper Therapeutics (JSPR)
RBC Capital Keeps Their Buy Rating on Jasper Therapeutics (JSPR) In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report), with a price target of $68.00. The company’s shares closed yesterday at $18.85. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Pacira Pharmaceuticals, and Viridian Therapeutics. According to TipRanks, Renza has an average return of 13.8% and a 45.27% success rate on recommended stocks. Jasper Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $72.71, which is a 285.73% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $90.00 price target. JasperReports Server in – Reviews, Features, Pricing The company has a one-year high of $31.01 and a one-year low of $4.00. Currently, Jasper Therapeutics has an average volume of 171.6K. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today. Jasper Therapeutics (JSPR) Company Description: Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Jaspersoft Business Intelligence Suite in – Reviews, Features How Small Businesses Can Use AI To Get A Competitive Edge Aug 14, 2024,01:15pm EDT 20 Key Factors That Contribute To Business Success”,”scope”:{“topStory”:{“index”:1,”title”:”20 Key Factors That Contribute To Business Success”,”image”:”https://specials-images.forbesimg.com/imageserve/66bbc718f1ae0243844d2025/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”01:15″,”amPm”:”pm”,”isEDT”:true,”unformattedDate”:1723655700000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/20-key-factors-that-contribute-to-business-success/”}},”id”:”81o7151ocoi800″},{“textContent”:” Aug 14, 2024,10:30am EDT Reporting & Embedded Analytics Solutions Jaspersoft DTC Vs. Marketplace: How To Choose The Right Channel Strategy”,”scope”:{“topStory”:{“index”:2,”title”:”DTC Vs. Marketplace: How To Choose The Right Channel Strategy”,”image”:”https://specials-images.forbesimg.com/imageserve/66bbc8e8626eb7c8941dc46b/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”10:30″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723645800000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/dtc-vs-marketplace-how-to-choose-the-right-channel-strategy/”}},”id”:”dre210a113lk00″},{“textContent”:” Aug 14, 2024,10:15am EDT Workplace Burnout: Identifying And Addressing It”,”scope”:{“topStory”:{“index”:3,”title”:”Workplace Burnout: Identifying And Addressing It”,”image”:”https://specials-images.forbesimg.com/imageserve/66bbc7fb811a20a82afebf37/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”10:15″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723644900000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/workplace-burnout-identifying-and-addressing-it/”}},”id”:”cr3clbj362io00″},{“textContent”:” Aug 14, 2024,10:00am EDT Jaspersoft Software Reviews, Demo & Pricing – Turning Data Into Dollars: A Strategic Approach For Leaders”,”scope”:{“topStory”:{“index”:4,”title”:”Turning Data Into Dollars: A Strategic Approach For Leaders”,”image”:”https://specials-images.forbesimg.com/imageserve/62601f40cff8e83e2777648b/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”10:00″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723644000000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/turning-data-into-dollars-a-strategic-approach-for-leaders/”}},”id”:”rb4ci7rc8rng0″},{“textContent”:” Aug 14, 2024,10:00am EDT On-Demand Talent Can Push Key Objectives Forward Amid An Increase In M&A Deals”,”scope”:{“topStory”:{“index”:5,”title”:”On-Demand Talent Can Push Key Objectives Forward Amid An Increase In M&A Deals”,”image”:”https://specials-images.forbesimg.com/imageserve/66bbd23187f655bb26940985/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”10:00″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723644000000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/on-demand-talent-can-push-key-objectives-forward-amid-an-increase-in-ma-deals/”}},”id”:”84ma0iigk2q000″},{“textContent”:” Aug 14, 2024,09:45am EDT Disaster-Proof Leadership: Navigating Transformation In A Crisis”,”scope”:{“topStory”:{“index”:6,”title”:”Disaster-Proof Leadership: Navigating Transformation In A Crisis”,”image”:”https://specials-images.forbesimg.com/imageserve/66ba4be4e1706300bd21d4ca/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”09:45″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723643100000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/disaster-proof-leadership-navigating-transformation-in-a-crisis/”}},”id”:”4p1qbncl3iag00″},{“textContent”:” Aug 14, 2024,09:30am EDT Managing Competing Priorities As A Leader”,”scope”:{“topStory”:{“index”:7,”title”:”Managing Competing Priorities As A Leader”,”image”:”https://specials-images.forbesimg.com/imageserve/66881b64fc16e7ba2b955ba6/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”09:30″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723642200000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/managing-competing-priorities-as-a-leader/”}},”id”:”blg1g60p19dk00″},{“textContent”:” Aug 14, 2024,09:15am EDT Achieving Success Through Time: Knowing When To Innovate And When To Stay True To Your Roots”,”scope”:{“topStory”:{“index”:8,”title”:”Achieving Success Through Time: Knowing When To Innovate And When To Stay True To Your Roots”,”image”:”https://specials-images.forbesimg.com/imageserve/66bbc43ab9152f9b92974d87/290×0.jpg”,”isHappeningNowArticle”:false,”date”:{“monthDayYear”:”Aug 14, 2024″,”hourMinute”:”09:15″,”amPm”:”am”,”isEDT”:true,”unformattedDate”:1723641300000},”uri”:”https://www.forbes.com/councils/forbesbusinesscouncil/2024/08/14/achieving-success-through-time-knowing-when-to-innovate-and-when-to-stay-true-to-your-roots/”}},”id”:”88p9mcjpqnko0″}],”breakpoints”:[{“breakpoint”:”@media all and (max-width: 767px)”,”config”:{“enabled”:false}},{“breakpoint”:”@media all and (max-width: 768px)”,”config”:{“inView”:2,”slidesToScroll”:1}},{“breakpoint”:”@media all and (min-width: 1681px)”,”config”:{“inView”:6}}]}; Buy Rating Reaffirmed for Jasper Therapeutics on Strong Clinical Performance and Market Potential BTIG analyst Justin Zelin has reiterated their bullish stance on JSPR stock, giving a Buy rating yesterday. Justin Zelin has given his Buy rating due to a combination of factors including Jasper Therapeutics’ strong performance in their clinical studies and the potential for their drug candidate, briq, to offer competitive efficacy and safety. Jasper’s enrollment for their BEACON study proceeded more rapidly than expected, enabling them to present comprehensive data sooner and add a new dosage cohort to their trial. This robust enrollment pace suggests a high level of interest and confidence in the treatment, which Zelin views as a positive indicator for the company’s prospects. The addition of the 180mg dose every eight weeks also presents an opportunity for Jasper to refine their dose selection for future registrational studies at a minimal cost. Furthermore, the expected data from the SPOTLIGHT study in the fourth quarter could set Jasper’s briq apart on safety, especially in light of competing treatments like Celldex’s barzolvolimab, which has shown a risk of anaphylaxis. Zelin anticipates that the risk of such adverse events with briq could be lower due to its rational design and lower observed adverse event rates to date. Additionally, Jasper’s financial performance in the second quarter was better than consensus estimates, and its planned expansion into severe asthma presents further growth opportunities. With these factors in mind, Zelin reaffirms his Buy rating and $90 price target, looking ahead to meaningful catalysts that could significantly impact Jasper’s valuation. In another report released yesterday, Capital One Financial also assigned a Buy rating to the stock with a $55.00 price target. JSPR’s price has also changed slightly for the past six months – from $17.820 to $18.850, which is a 5.78% increase. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today. Jasper Therapeutics (JSPR) Company Description: Amplitude Healthcare Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Sam Altman warned OpenAI will ‘steamroll’ AI startups. I run one. Here’s why I’m not worried Building an AI startup in 2024 is a lot of things. It is exciting, surreal, and rewarding. We are building to solve real user problems using a new, groundbreaking technology in the early innings of what is likely the next big wave in tech. Awesome, right? Yes, but it can also be equal parts terrifying. Spend any amount of time online in tech communities and you are sure to see headlines declaring that the most recent AI breakthrough spells the end for most AI startups. In a space where breakthroughs happen by the week, this can be tiresome. It is not just tech journalists, opinionists, and fire-stokers making these declarations. It also comes directly from the people responsible for launching these breakthroughs. A few months back on the 20VC podcast, OpenAI CEO Sam Altman …